SFJ XI (Apellis)

SFJ and Apellis Pharmaceuticals (Nasdaq: APPL) collaborated on the development of APL-2, a novel therapeutic targeting complement, in haematologic indications including Paroxysmal Nocturnal Haemoglobinuria (PNH). With the drug now approved, SFJ is receiving payments for its funding by Apellis.